Drug Approval | May 11, 2022
Alembic Pharmaceuticals receives USFDA approval for Arformoterol Tartrate
This ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies
This ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies
Arformoterol Tartrate had estimated annual sales of US $ 251 million in the U.S. (IQVIA MAT December 2021)
The acquisition of these two brands expands Lupin's portfolio of inhalation products in the U.S.
Arformoterol Tartrate Inhalation Solution, 15 mcg/2 mL, Unit-Dose Vials will be manufactured in the company’s North American manufacturing facility based in Monroe, North Carolina
Arformoterol Tartrate Inhalation Solution 15 mcg/2 mL is AN-rated generic therapeutic equivalent version of Sunovion Pharmaceuticals Inc.’s Brovana
Arformoterol Tartrate Inhalation Solution is for treatment of bronchoconstriction
Subscribe To Our Newsletter & Stay Updated
